Ventyx bolsters coffers with $51M, autoimmune expertise

Six months after launching with a $114 million round led by venBio, Ventyx has raised $51 million in a series B convertible preferred stock deal led by Citadel’s Surveyor Capital, added a CMO and rounded out its board with autoimmune specialists.

Jörn Drappa is Ventyx Biosciences Inc.’s new CMO, while Sheila Gujrathi is now executive chair. Gujrathi is founder and former CEO of Gossamer Bio Inc. (NASDAQ:GOSS), while Drappa was EVP of R&D at Horizon Discovery Group plc. ...